<article id="almenar_2009_p" class="slide" data-ag-slide-name="Almenar 2009 (P)">
    <div class="basic">
      <h1 data-ag-editable="Almenar 2009 (P) Main Title">Neulasta<sup>®</sup> once per cycle provides reduction in incidence of FN and FN-related complications<sup>1</sup></h1>
      <!--
      <div id="ne_page3_data_top_p" class="red_subtitle" data-ag-editable="Almenar 2009 (P) Top Copy">Proportion of patients experiencing chemotherapy induced neutropenia-related complications in the LEARN study<sup>†</sup></div>
    -->
      <div id="ne_page3_graph1_p" class="main_content_style">

         <img src="content/images/pragmatist_pages/neulasta_efficacy/ne_page3_graph1.png" width="602" height="314" data-ag-editable="Almenar 2009 (P) Graph" />
          <div id="almenar_2009_p_graph_content"data-ag-editable="Almenar 2009 (P) Graph Content">
              <h2 id="graph_title">Proportion of patients experiencing chemotherapy induced neutropenia-related<br/>complications in the LEARN study<sup>†</sup></h2>
              <p id="graph_legend1">Neulasta<sup>®</sup> (n=75)</p>
              <p id="graph_legend2">Daily G-CSF<sup>‡</sup> (n=111)</p>
              <p id="graph_vertical_axis_title">% of patients experiencing<br/>chemotherapy-related complications</p>
              <p id="graph_left_text">Febrile Neutropenia</p>
              <p id="graph_mid_text">Neutropenia-related<br/>dose reductions</p>
              <p id="graph_right_text">Hospitalization<br/>due to FN</p>
              <p id="graph_bottom_text">Adapted from Almenar D <span class="et_al">et al.</span> Eur J Cancer Care(Engl); 2009; 18(3);280-286</p>

              <p id="graph_bar1_value">24.3</p>
              <p id="graph_bar2_value">10.7</p>
              <p id="graph_bar3_value">20.7</p>
              <p id="graph_bar4_value">6.7</p>
              <p id="graph_bar5_value">19.8</p>
              <p id="graph_bar6_value">9.3</p>

          </div>
      </div>
      <div id="ne_page3_data_bottom_p">
        <ul class="red_dot_list" data-ag-editable="Almenar 2009 (P) Bottom List Copy">
           <li>The median number of injections per cycle was 6 (range 1–13) among patients receiving daily G-CSF as primary prophylaxis<sup>1</sup></li>
        </ul>
      </div>
    </div>
    <!-- Reference Information Starts -->
    <div class="enlarge_graph" id="enlarge_graph_almenar_2009_p"></div>
    <div class="lightbox_data" id="almenar_2009_p_refs">
       <div class="main_content_style">
          <p><strong data-ag-editable="Almenar 2009 (P) References Title">References:</strong></p>
          <div data-ag-editable="Almenar 2009 (P) References List">
             <ol>
                <li>von Minckwitz G <em>et al.</em> Eur J Cancer 2009; 45:608-617.</li>
             </ol>
          </div>
         <!-- <p data-ag-editable="Almenar 2009 (P) References Bottom Copy">† LEARN was a multi-centre, retrospective, observational study that compared the use of daily G-CSF and Neulasta<sup>®</sup> in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy (n=248). 111 patients received daily G-CSF, 75 patients received Neulasta, and 62 patients received both.<br /><br />
          ‡ filgrastim or lenograstim</p>-->
       </div>
    </div>
    <!-- Reference Information Ends -->
    <div class="large_graph_container">
            <div id="almenar_2009_p_large" class="large_graph">
              <div class="large_style">
               <img src="content/images/pragmatist_pages/neulasta_efficacy/page3_graph_large.png" width="827" height="485" data-ag-editable="Cooper 2011 Prag Large Graph" />
                  <div id="almenar_2009_p_graph_content_large"data-ag-editable="Almenar 2009 (P) Graph Content">
                      <h2 id="graph_title_large">Proportion of patients experiencing chemotherapy induced neutropenia-related<br/>complications in the LEARN study<sup>†</sup></h2>
                      <p id="graph_legend1_large">Neulasta<sup>®</sup> (n=75)</p>
                      <p id="graph_legend2_large">Daily G-CSF<sup>‡</sup> (n=111)</p>
                      <p id="graph_vertical_axis_title_large">% of patients experiencing<br/>chemotherapy-related complications</p>
                      <p id="graph_left_text_large">Febrile Neutropenia</p>
                      <p id="graph_mid_text_large">Neutropenia-related<br/>dose reductions</p>
                      <p id="graph_right_text_large">Hospitalization<br/>due to FN</p>
                      <p id="graph_bottom_text_large">Adapted from Almenar D <span class="et_al">et al.</span> Eur J Cancer Care(Engl); 2009; 18(3);280-286</p>

                      <p id="graph_bar1_value_large">24.3</p>
                      <p id="graph_bar2_value_large">10.7</p>
                      <p id="graph_bar3_value_large">20.7</p>
                      <p id="graph_bar4_value_large">6.7</p>
                      <p id="graph_bar5_value_large">19.8</p>
                      <p id="graph_bar6_value_large">9.3</p>

                  </div>
               </div>
            </div>
    </div>
</article>